c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme-Reference-Cited by-同舟云学术

c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme

Published:2009-04-08 Issue:3 Volume:218 Page:292-300
ISSN:0022-3417
Container-title:The Journal of Pathology
language:en
Short-container-title:J. Pathol.

Author:

Snyder Eric L,Sandstrom Deborah J,Law Kenneth,Fiore Christopher,Sicinska Ewa,Brito Joseph,Bailey Dyane,Fletcher Jonathan A,Loda Massimo,Rodig Scott J,Dal Cin Paola,Fletcher Christopher DM

Funder

Molecular Oncologic Pathology of the Dana Farber Cancer Institute and Brigham and Women's Hospital

Publisher

Wiley

Subject

Pathology and Forensic Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/path.2564/fullpdf

Reference20 articles.

1. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon;Italiano;Int J Cancer,2008

2. ASK1 (MAP3K5) as a potential therapeutic target in malignant fibrous histiocytomas with 12q14-q15 and 6q23 amplifications;Chibon;Genes Chromosomes Cancer,2004

3. JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas;Mariani;Cancer Cell,2007

4. Retinoblastoma protein positively regulates terminal adipocyte differentiation through direct interaction with C/EBPs;Chen;Genes Dev,1996

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GLI1 Coamplification in Well-Differentiated/Dedifferentiated Liposarcomas: Clinicopathologic and Molecular Analysis of 92 Cases;Modern Pathology;2024-06

2. Mesenchymal Stem Cells and Sarcoma;Comprehensive Hematology and Stem Cell Research;2024

3. Case Report: Primary low-grade dedifferentiated liposarcoma of the urinary bladder with molecular confirmation;Frontiers in Oncology;2023-10-10

4. Impact of supraphysiologic MDM2 expression on chromatin networks and therapeutic responses in sarcoma;Cell Genomics;2023-07

5. The spectrum and significance of secondary (co‐occurring) genetic alterations in sarcomas: the hallmarks of sarcomagenesis;The Journal of Pathology;2023-06-22